Cullinan Oncology Net Worth
Cullinan Oncology Net Worth Breakdown | CGEM |
Cullinan Oncology Net Worth Analysis
Cullinan Oncology's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Cullinan Oncology's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Cullinan Oncology's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Cullinan Oncology's net worth analysis. One common approach is to calculate Cullinan Oncology's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Cullinan Oncology's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Cullinan Oncology's net worth. This approach calculates the present value of Cullinan Oncology's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Cullinan Oncology's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Cullinan Oncology's net worth. This involves comparing Cullinan Oncology's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Cullinan Oncology's net worth relative to its peers.
Enterprise Value |
|
To determine if Cullinan Oncology is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Cullinan Oncology's net worth research are outlined below:
| Cullinan Oncology generated a negative expected return over the last 90 days | |
| Cullinan Oncology has high historical volatility and very poor performance | |
| Net Loss for the year was (153.16 M) with profit before overhead, payroll, taxes, and interest of 18.94 M. | |
| Cullinan Oncology LLC currently holds about 611 M in cash with (134.28 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 13.4, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Cullinan Oncology has a poor financial position based on the latest SEC disclosures | |
| Over 96.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from simplywall.st: Cullinan Therapeutics Is In A Good Position To Deliver On Growth Plans |
Cullinan Oncology uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Cullinan Oncology LLC. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Cullinan Oncology's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Cullinan Oncology's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Cullinan Oncology is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cullinan Oncology LLC backward and forwards among themselves. Cullinan Oncology's institutional investor refers to the entity that pools money to purchase Cullinan Oncology's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Alliancebernstein L.p. | 2024-06-30 | 1.7 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 1.7 M | Avidity Partners Management Lp | 2024-06-30 | 1.6 M | Vr Adviser, Llc | 2024-06-30 | 1.4 M | Holocene Advisors, Lp | 2024-06-30 | 1.3 M | Marshall Wace Asset Management Ltd | 2024-06-30 | 1.2 M | Braidwell Lp | 2024-09-30 | 1.2 M | Orbimed Advisors, Llc | 2024-06-30 | 1.1 M | Nextech Invest Ag | 2024-09-30 | 1.1 M | Mpm Oncology Impact Management Lp | 2024-09-30 | 7.6 M | Bvf Inc | 2024-09-30 | 5.8 M |
Follow Cullinan Oncology's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 732.5 M.Market Cap |
|
Project Cullinan Oncology's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.32) | (0.30) | |
| Return On Capital Employed | (0.42) | (0.40) | |
| Return On Assets | (0.32) | (0.30) | |
| Return On Equity | (0.34) | (0.32) |
When accessing Cullinan Oncology's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Cullinan Oncology's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Cullinan Oncology's profitability and make more informed investment decisions.
Evaluate Cullinan Oncology's management efficiency
Cullinan Oncology LLC has return on total asset (ROA) of (0.204) % which means that it has lost $0.204 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2653) %, meaning that it created substantial loss on money invested by shareholders. Cullinan Oncology's management efficiency ratios could be used to measure how well Cullinan Oncology manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of November 2024, Return On Tangible Assets is likely to grow to -0.3. In addition to that, Return On Capital Employed is likely to grow to -0.4. At this time, Cullinan Oncology's Total Assets are very stable compared to the past year. As of the 22nd of November 2024, Other Current Assets is likely to grow to about 13.8 M, while Non Current Assets Total are likely to drop about 3.8 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 10.94 | 11.48 | |
| Tangible Book Value Per Share | 10.94 | 11.48 | |
| Enterprise Value Over EBITDA | (1.72) | (1.81) | |
| Price Book Value Ratio | 0.93 | 0.98 | |
| Enterprise Value Multiple | (1.72) | (1.81) | |
| Price Fair Value | 0.93 | 0.98 | |
| Enterprise Value | -78.7 M | -74.8 M |
Cullinan Oncology LLC benefits from a proactive management team that anticipates market trends. Our analysis delves into how this proactive stance influences financial metrics and stock valuation.
Enterprise Value Revenue 11.5457 | Return On Equity (0.27) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cullinan Oncology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cullinan Oncology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cullinan Oncology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Cullinan Oncology Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 8th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
8K | 7th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 31st of October 2024 Other Reports | ViewVerify |
Cullinan Oncology Earnings per Share Projection vs Actual
Cullinan Oncology Corporate Management
| Jennifer Michaelson | Chief Officer | Profile | |
| Kerry Whalen | Director Devel | Profile | |
| Jeffrey Trigilio | CFO Treasurer | Profile | |
| Mary Fenton | Chief Officer | Profile | |
| Jacquelyn JD | Chief Officer | Profile | |
| MBA MD | Chief Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cullinan Oncology LLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cullinan Oncology. If investors know Cullinan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cullinan Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.84) | Return On Assets (0.20) | Return On Equity (0.27) |
The market value of Cullinan Oncology LLC is measured differently than its book value, which is the value of Cullinan that is recorded on the company's balance sheet. Investors also form their own opinion of Cullinan Oncology's value that differs from its market value or its book value, called intrinsic value, which is Cullinan Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cullinan Oncology's market value can be influenced by many factors that don't directly affect Cullinan Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cullinan Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cullinan Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cullinan Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.